Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: J Hepatol. 2015 Jul 15;63(5):1103–1110. doi: 10.1016/j.jhep.2015.06.035

Figure 1.

Figure 1

Median decrease in HCV RNA levels (log10 international units (IU)/ml) in African American participants in the VIRAHEP-C study during the first 28 days of treatment with pegylated-interferon-α plus ribavirin. P = 0.003 for the mean differences in HCV RNA levels at day 28 for each of the three IFNL4-ΔG/TT (rs368234815) genotype groups relative to the respective IFNL3 rs4803217 genotype groups.